•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Emera Q3 Earnings Call Highlights
Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta
Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data
Emera Reports 2026 Third Quarter Financial Results and Unveils $21.5 Billion Five-Year Capital Plan
Crossmark Global Holdings Inc. Buys 21,825 Shares of eMagin Corporation $EMA
Pfizer's TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
Emera Incorporated (EMA.TO) – What Are Researchers Saying About This Stock?
Emera Declares Quarterly Dividends
Emera Teleconference on November 6 to Discuss Q3 2026 Results and 2027-2031 Capital Plan
Emera (NYSE: EMA) agrees $72 billion merger with Canadian Utilities and ATCO spin-off
Emera to combine with Canadian Utilities in largest all-Canadian merger on record
Canadian Utilities, Emera Strike C$72B Utility Merger Deal
Emera, Canadian Utilities Unveil C$72B Merger to Create Utility Powerhouse
Emera, Canadian Utilities Unveil C$72B Merger to Create Utility Powerhouse
Emera, ATCO and Canadian Utilities Announce Transformational Agreement to Create Canadian Utility and Energy Infrastructure Powerhouse
Emera Announces Increase in Common Dividend
Emera Incorporated (TSE:EMA) Given Consensus Rating of “Moderate Buy” by Brokerages
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
Engineers Gate Manager LP Purchases 17,165 Shares of eMagin Corporation $EMA
Already premium?